Coffee intake and decreased amyloid pathology in human brain

for the KBASE Research Group

Research output: Contribution to journalArticle

Abstract

Several epidemiological and preclinical studies supported the protective effect of coffee on Alzheimer’s disease (AD). However, it is still unknown whether coffee is specifically related with reduced brain AD pathologies in human. Hence, this study aims to investigate relationships between coffee intake and in vivo AD pathologies, including cerebral beta-amyloid (Aβ) deposition, the neurodegeneration of AD-signature regions, and cerebral white matter hyperintensities (WMH). A total of 411 non-demented older adults were included. Participants underwent comprehensive clinical assessment and multimodal neuroimaging including [11C] Pittsburgh compound B-positron emission tomography (PET), [18F] fluorodeoxyglucose PET, and magnetic resonance imaging scans. Lifetime and current coffee intake were categorized as follows: no coffee or <2 cups/day (reference category) and ≥2 cups/day (higher coffee intake). Lifetime coffee intake of ≥2 cups/day was significantly associated with a lower Aβ positivity compared to coffee intake of <2 cups/day, even after controlling for potential confounders. In contrast, neither lifetime nor current coffee intake was not related to hypometabolism, atrophy of AD-signature region, and WMH volume. The findings suggest that higher lifetime coffee intake may contribute to lowering the risk of AD or related cognitive decline by reducing pathological cerebral amyloid deposition.

Original languageEnglish
Article number270
JournalTranslational psychiatry
Volume9
Issue number1
DOIs
StatePublished - 1 Dec 2019

Fingerprint

Coffee
Amyloid
Pathology
Brain
Alzheimer Disease
Positron-Emission Tomography
Fluorodeoxyglucose F18
Brain Diseases
Neuroimaging
Atrophy
Epidemiologic Studies
Magnetic Resonance Imaging

Cite this

for the KBASE Research Group. / Coffee intake and decreased amyloid pathology in human brain. In: Translational psychiatry. 2019 ; Vol. 9, No. 1.
@article{e44a721638584418b078957d89dd9be9,
title = "Coffee intake and decreased amyloid pathology in human brain",
abstract = "Several epidemiological and preclinical studies supported the protective effect of coffee on Alzheimer’s disease (AD). However, it is still unknown whether coffee is specifically related with reduced brain AD pathologies in human. Hence, this study aims to investigate relationships between coffee intake and in vivo AD pathologies, including cerebral beta-amyloid (Aβ) deposition, the neurodegeneration of AD-signature regions, and cerebral white matter hyperintensities (WMH). A total of 411 non-demented older adults were included. Participants underwent comprehensive clinical assessment and multimodal neuroimaging including [11C] Pittsburgh compound B-positron emission tomography (PET), [18F] fluorodeoxyglucose PET, and magnetic resonance imaging scans. Lifetime and current coffee intake were categorized as follows: no coffee or <2 cups/day (reference category) and ≥2 cups/day (higher coffee intake). Lifetime coffee intake of ≥2 cups/day was significantly associated with a lower Aβ positivity compared to coffee intake of <2 cups/day, even after controlling for potential confounders. In contrast, neither lifetime nor current coffee intake was not related to hypometabolism, atrophy of AD-signature region, and WMH volume. The findings suggest that higher lifetime coffee intake may contribute to lowering the risk of AD or related cognitive decline by reducing pathological cerebral amyloid deposition.",
author = "{for the KBASE Research Group} and Kim, {Jee Wook} and Byun, {Min Soo} and Dahyun Yi and Lee, {Jun Ho} and Jeon, {So Yeon} and Gijung Jung and Lee, {Han Na} and Sohn, {Bo Kyung} and Lee, {Jun Young} and Kim, {Yu Kyeong} and Shin, {Seong A.} and Sohn, {Chul Ho} and Lee, {Dong Young}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41398-019-0604-5",
language = "English",
volume = "9",
journal = "Translational Psychiatry",
issn = "2158-3188",
publisher = "Nature Publishing Group",
number = "1",

}

Coffee intake and decreased amyloid pathology in human brain. / for the KBASE Research Group.

In: Translational psychiatry, Vol. 9, No. 1, 270, 01.12.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Coffee intake and decreased amyloid pathology in human brain

AU - for the KBASE Research Group

AU - Kim, Jee Wook

AU - Byun, Min Soo

AU - Yi, Dahyun

AU - Lee, Jun Ho

AU - Jeon, So Yeon

AU - Jung, Gijung

AU - Lee, Han Na

AU - Sohn, Bo Kyung

AU - Lee, Jun Young

AU - Kim, Yu Kyeong

AU - Shin, Seong A.

AU - Sohn, Chul Ho

AU - Lee, Dong Young

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Several epidemiological and preclinical studies supported the protective effect of coffee on Alzheimer’s disease (AD). However, it is still unknown whether coffee is specifically related with reduced brain AD pathologies in human. Hence, this study aims to investigate relationships between coffee intake and in vivo AD pathologies, including cerebral beta-amyloid (Aβ) deposition, the neurodegeneration of AD-signature regions, and cerebral white matter hyperintensities (WMH). A total of 411 non-demented older adults were included. Participants underwent comprehensive clinical assessment and multimodal neuroimaging including [11C] Pittsburgh compound B-positron emission tomography (PET), [18F] fluorodeoxyglucose PET, and magnetic resonance imaging scans. Lifetime and current coffee intake were categorized as follows: no coffee or <2 cups/day (reference category) and ≥2 cups/day (higher coffee intake). Lifetime coffee intake of ≥2 cups/day was significantly associated with a lower Aβ positivity compared to coffee intake of <2 cups/day, even after controlling for potential confounders. In contrast, neither lifetime nor current coffee intake was not related to hypometabolism, atrophy of AD-signature region, and WMH volume. The findings suggest that higher lifetime coffee intake may contribute to lowering the risk of AD or related cognitive decline by reducing pathological cerebral amyloid deposition.

AB - Several epidemiological and preclinical studies supported the protective effect of coffee on Alzheimer’s disease (AD). However, it is still unknown whether coffee is specifically related with reduced brain AD pathologies in human. Hence, this study aims to investigate relationships between coffee intake and in vivo AD pathologies, including cerebral beta-amyloid (Aβ) deposition, the neurodegeneration of AD-signature regions, and cerebral white matter hyperintensities (WMH). A total of 411 non-demented older adults were included. Participants underwent comprehensive clinical assessment and multimodal neuroimaging including [11C] Pittsburgh compound B-positron emission tomography (PET), [18F] fluorodeoxyglucose PET, and magnetic resonance imaging scans. Lifetime and current coffee intake were categorized as follows: no coffee or <2 cups/day (reference category) and ≥2 cups/day (higher coffee intake). Lifetime coffee intake of ≥2 cups/day was significantly associated with a lower Aβ positivity compared to coffee intake of <2 cups/day, even after controlling for potential confounders. In contrast, neither lifetime nor current coffee intake was not related to hypometabolism, atrophy of AD-signature region, and WMH volume. The findings suggest that higher lifetime coffee intake may contribute to lowering the risk of AD or related cognitive decline by reducing pathological cerebral amyloid deposition.

UR - http://www.scopus.com/inward/record.url?scp=85073751628&partnerID=8YFLogxK

U2 - 10.1038/s41398-019-0604-5

DO - 10.1038/s41398-019-0604-5

M3 - Article

C2 - 31641100

AN - SCOPUS:85073751628

VL - 9

JO - Translational Psychiatry

JF - Translational Psychiatry

SN - 2158-3188

IS - 1

M1 - 270

ER -